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ABSTRACT 
Synthesis of a series of various 2, 5-disubstituted-1, 3, 4-oxadiazole derivatives (7a-7v) have been done previously. These novel synthesized 
derivatives (7a-7v) have been tested for their antibacterial activity against Gram +ve S. aureus and Gram -ve E. Coli bacterias by broth dilution 
method. A comparative study has been done for all derivatives.  Based on the visual turbidity, the  MIC of the evaluated molecules has been 
studied, the evaluation concentration was used single therefore, the exact MIC could not determined and results are represented in less than 
and more than based on growth of microorganism. To get more exact MIC of the tested molecules need to be evaluated at low concentration. 
Further testing for all compounds at lower concentrations is required to compare their activity with standard Streptomycin at  its MIC to get 
exact MIC the synthesized compounds. 
Previously novel synthesized derivatives are; 2-(phenoxymethyl)-5-phenyl-1, 3, 4-oxadiazole (7a), 4-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-
yl)aniline  (7b), 3-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl) aniline (7c), 2-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7d), 2, 4-
dinitro-6-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7e), 2-(4-(methylthio)benzyl)-5-(phenoxymethyl)-1,3,4-oxadiazole (7f), 2-((2, 4-
dichlorophenoxy) methyl)-5-phenyl-1,3,4-oxadiazole (7g), 4-(5-((2, 4-dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7h), 3-(5-((2, 4-
dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7i), 2-(5-((2, 4-dichlorophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl)phenol (7j), 2-(5-((2, 4-
dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)-4,6-dinitrophenol (7k), 2-((2,4-dichlorophenoxy) methyl)-5-(4-(methylthio)benzyl)-1,3,4-
oxadiazole (7l), (Z)-2-((2, 4-dichlorophenoxy) methyl)-5-styryl-1,3,4-oxadiazole (7m), (S)-4-(2-(5-((2,4-dichlorophenoxy) methyl)-1, 3, 4-
oxadiazol-2-yl)propyl)phenol (7n), 2-((4-nitrophenoxy) methyl)-5-phenyl-1, 3, 4-oxadiazole (7o), 4-(5-((4-nitrophenoxy)methyl)-1,3,4-
oxadiazol-2-yl)aniline (7p), 3-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)aniline (7q), 2-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-
yl)phenol (7r), 2, 4-dinitro-6-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)phenol (7s), 2-(4-(methylthio) benzyl)-5-((4-nitrophenoxy) 
methyl)-1,3,4-oxadiazole (7t), (Z)-2-((4-nitrophenoxy)methyl)-5-styryl-1,3,4-oxadiazole (7u) and 5-((2, 4-dichlorophenoxy) methyl)-1,3,4-
oxadiazole-2-thiol (7v). 
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Table 1: Various derivatives of 2,5-disubstituted-1,3,4-oxadiazole derivatives (7a-7v) 
Sr. No. Compound R R 
1 7a -H -C6H5 
2 7b -H 4-NH2C6H5- 
3 7c -H 3-NH2C6H5- 
4 7d -H 2-OHC6H5- 
5 7e -H 2- OH-3,5-dinitroC6H5- 
6 7f -H 1-CH2-4-SCH3C6H5- 
7 7g Chloro at position 2 and 4 -C6H5 
8 7h Chloro at position 2 and 4 4-NH2C6H5- 
9 7i Chloro at position 2 and 4 3-NH2C6H5- 
10 7j Chloro at position 2 and 4 2-OHC6H5- 
11 7k Chloro at position 2 and 4 2- OH-3,5-dinitroC6H5- 
12 7l Chloro at position 2 and 4 1-CH2-4-SCH3C6H5- 
13 7m Chloro at position 2 and 4 C6H5CH=CH- 
14 7n Chloro at position 2 and 4 4-OHC6H5CH2(NH2)- 
15 7o Nitro group at position 4 -C6H5 
16 7p Nitro group at position 4 4-NH2C6H5- 
17 7q Nitro group at position 4 3-NH2C6H5- 
18 7r Nitro group at position 4 2-OHC6H5- 
19 7s Nitro group at position 4 2- OH-3,5-dinitroC6H5- 
20 7t Nitro group at position 4 1-CH2-4-SCH3C6H5- 
21 7u Nitro group at position 4 C6H5CH=CH- 
22 7v Chloro at position 2 and 4 -SH 
 
1. INTRODUCTION 
All synthesized derivatives (7a-7v) were subjected to 
antimicrobial evaluation against Escherichia coli and S. 
aureus microorganism using broth dilution method keeping 
appropriate positive and negative controls simultaneously.   
Infection: Infection is the invasion of an organism's body 
tissues by disease causing agents, there multiplication, and 
the reaction of host tissues to the infectious agents and the 
toxins they produce1,2.  
Anti-infectives: This term is used to describe any medicine 
that is capable of inhibiting the spread of an infectious 
organism or by killing the infectious organism3. 
Role of 1,3,4-Oxadiazole moiety in modern drug 
discovery. 
A broad range of substituted 1,3,4-oxadiazoles have 
ramarkable attention in the field of drug discovery because 
of their large spectrum of pharmacological activities. 
Oxadiazoles have been kept at a specific place in the field of 
medicinal chemistry due to its wide range of activities4. 
1,3,4-oxadiazole derivatives show anticonvulsant5, 
antimicrobial activity6, insecticide7, anti-tubercular activity8, 
anti-inflammatory activity9, cardiovascular activity10, 
antialzheimers activity11, anti-tumor agents12, antidiabetes13 
and spasmolytic activity14. 
2. EXPERIMENTAL 
2.1 Anti-microbial testing  
Activity of anti-infective agents may be demonstrated under 
suitable conditions by their inhibitory effect on 
microorganisms. The anti-microbial activity of the 
synthesized compounds was carried out by standard 
procedure using broth dilution method and minimum 
inhibitory concentration was determined by visual 
comparison with the negative control tubes.  
Detailed test procedure: 
2.1.1 Stock Solutions of test compounds and standard 
drug 
Compounds were taken as test samples along with a 
standard Streptomycin sample. Weight taken in the range of 
8-20 mg of each test compound and was dissolved in 1 ml of 
DMSO. For preparing stock solution of Streptomycin, 10 mg 
of Streptomycin was dissolved in 1 ml of water.    
2.1.2 Test organism 
The organisms employed in the in vitro testing of the 
compounds were Escherichia coli and S. aureus. All the 
cultures were maintained on nutrient broth agar 
(Microbiology grade, CDH Pvt. Ltd. New Delhi.) medium by 
periodic sub culturing. 
2.1.3 Preparation of Innoculum 
Procedure for the preparation of innoculum for both the 
strains was same. The innoculum was prepared from a 24-
hours old growth of organism on nutrient broth agar slant. 
To the agar slant, saline solution was added to obtain O.D 
value of 0.1 on photoelectric optical colorimeter. 0.5ml of 
this solution was further diluted to 20ml with use of saline.  
2.1.4 Preparation of Medium 
 1.3 gms of nutrient broth (Microbiology grade, CDH Pvt. Ltd. 
New Delhi.) was dissolved in 100 ml of sterile distilled 
water.  
2.1.5 Addition of drug, innoculum solution to medium 
From diluted innoculum solution prepared, 100μl was added 
to separate test tube each containing 0.9ml of medium. 25 μl 
solution of test stock solution was added in four separate 
test tube containing 0.9ml of medium with 100 μl 
innoculum. The tests were carried out in duplicate. Apart 
from putting the controls of standard drug (Streptomycin), 
controls with dimethylsulphoxide (DMSO) were used. DMSO 
(positive control) is DMSO inoculated with organisms and 
dimethylsulphoxide (negative control) is plain DMSO. For 
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incubation, test tubes were kept in incubator at 35°C for 24 
hours.   
2.1.6 Observations  
At the end of incubation period, the results were interpreted 
by comparison with negative control. The lowest 
concentration of test compound which showed inhibitory 
effect on growth on visual distinction was taken as minimum 
inhibitory concentration (MIC) and visual turbidity was 
consider for MIC of the test molecules; standard drug and 
DMSO positive and negative control visual turbidity were 
recorded. 
The synthesized derivatives were tested for antimicrobial 
activity against Escherichia coli and S. aureus microorganism 
using broth dilution method keeping appropriate positive 
and negative controls simultaneously.  
Visual turbidity of evaluated compounds is given in Table 2
 
Table 2: Visual turbidity of evaluated compounds 
Sr. 
No. 
Mol. 
ID 
E.coli  S. aureus  Sr. No. Mol. ID E.coli  S. aureus  
Visual 
turbidity 
Visual 
turbidity 
Visual 
turbidity 
Visual 
turbidity 
1 7a _ _ 13 7m _ _ 
2 7b _ _ 14 7n + + 
3 7c _ _ 15 7o _ _ 
4 7d _ _ 16 7p + _ 
5 7e _ _ 17 7q _ + 
6 7f _ _ 18 7r _ _ 
7 7g _ _ 19 7s + _ 
8 7h _ _ 20 7t _ _ 
9 7i _ _ 21 7u + _ 
10 7j _ _ 22 7v _ _ 
11 
7k 
+ + 23 Streptomycin _ _ 
12 7l + _ _ Positive ++ ++ 
- =No Turbidity (No bacterial growth), + =  Turbidity (Bacterial growth) 
 
Based on the visual turbidity, the  MIC of the evaluated 
molecules is given in Table 3 the evaluation concentration 
was used single therefore, the exact MIC could not 
determined and results are represented in less than and 
more than based on growth of microorganism. To get more 
exact MIC of the tested molecules need to be evaluated at 
low concentration.  
The evaluation results of the single concentration is 
tabulated in Table 3
 
Table 3: Testing result of evaluated compounds 
Sr. No. Comp- 
ound 
E. coli   S. aureus  Sr. 
No. 
Comp- 
ound 
E. coli   S. aureus  
(µg/ml) (µg/ml ) (µg/ml) (µg/ml ) 
1 7a < 600  < 600  13 7m < 450  < 450  
2 7b < 450  < 450  14 7n > 500  > 500  
3 7c < 500  < 500  15 7o < 25  < 25  
4 7d < 425  < 425  16 7p > 450  < 450  
5 7e < 350  < 350  17 7q < 375  > 375  
6 7f < 500  < 500  18 7r < 325  < 325  
7 7g < 325  < 325  19 7s > 475  < 475  
8 7h < 375  < 375 20 7t < 850  < 850  
9 7i < 375  < 375  21 7u > 300  < 300  
10 7j < 450  < 450  22 7v < 450  < 450  
11 7k > 750  > 750  23 Strepto- 
mycin 
< 450  < 450  
12 7l > 450  < 450  _ _ _ _ 
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3. RESULTS AND DISCUSSION  
Most of the tested molecules showed bacterial growth 
inhibition at tested concentration. The compounds (7e, 7g, 
7h, 7i and 7u) exhibited bacterial growth inhibition at 
concentration of less than 400μg/ml against both 
microorganisms. Compounds (7o) showed growth of 
inhibition at 25μg/ml against both microorganisms. Further 
testing for all compounds at lower concentrations is 
required to compare their activity with standard 
Streptomycin at its MIC to get exact MIC the synthesized 
compounds. 
4. REFERENCES 
1. Definition of "Infection" from several medical dictionaries, 
retrieved on 03, April, 2012. 
2. "Utilizing antibiotics agents effectively will preserve present 
day medication". News Ghana; 21, November, 2015. 
3. Plattener J., Chiron C. Cancer and Infectious diseases.  Annual 
Reports in Medicinal Chemistry, A. M. Doherty, Editor, 
ElseveirAcademic press, NewYork, 2003, 38, 163-172. 
4. Somani RR, Shirodkar PY Oxadiazole: A biologically important 
heterocycle. Chem Inform, 2011, 42. 
5. Zarghi A, Faizi M, Shafaghi B, Ahadian A, Khojastehpoor HR, et 
al., Design and synthesis of new 2-substituted-5-(2-
benzylthiophenyl)-1,3,4- oxadiazoles as benzodiazepine 
receptor agonists. Bioorg Med Chem Letters, 2005, 15, 3126-
3129. 
6. Sahin G, Palaska E, Ekizoglu M, Ozalp M Synthesis and 
antimicrobial activity of some 1, 3, 4-oxadiazole derivatives. II 
Farmaco, 2002, 57, 539-542. 
7. Cao S, Qian X, Song G, Huang Q Syntheses and insecticidal 
activity of new 2-(5-(trifluoromethyl) pyridyloxymethyl)-1, 3, 
4-oxadiazoles. Journal of Fluorine Chemistry, 2002, 117, 63-
66. 
8. Dewangan D, Pandey A, Sivakumar T, Rajavel R, Dubey RD. 
Synthesis of some novel 2, 5-disubstituted 1, 3, 4-oxadiazole 
and its analgesic, antiinflammatory, anti-bacterial and anti-
tubercular activity. Int J Chem Tech Res, 2010, 2, 1397-1412. 
9. Bansal S, Bala M, Suthar SK, Choudhary S, Bhattacharya S, et 
al. Design and synthesis of novel 2-phenyl-5-(1, 3-diphenyl-
1H-pyrazol-4-yl)-1, 3, 4-oxadiazoles as selective COX-2 
inhibitors with potent anti-inflammatory activity. European 
Journal of Medicinal Chemistry, 2014, 80, 167-174. 
10. Malhotra V, Pathak SR, Nath R, Mukherjee D, Shanker K. 
Substituted imidazole derivatives as novel cardiovascular 
agents. Bioorg Med Chem Letters, 2011, 21, 936-939. 
11. Saitoh M, Kunitomo J, Kimura E, Hayase Y, Kobayashi H, et al. 
Design, synthesis and structure–activity relationships of 1, 3, 
4-oxadiazole derivatives as novel inhibitors of glycogen 
synthase kinase-3β. Bioorg Med Chem, 2009, 17, 2017-2029. 
12. Sun J, Li M-H, Qian S-S, Guo F-J, Dang X-F, et al. Synthesis and 
antitumor activity of 1,3,4-oxadiazole possessing 1,4-
benzodioxan moiety as a novel class of potent methionine 
aminopeptidase type II inhibitors. Bioorg Med Chem Letters, 
2013, 23, 2876-2879. 
13. He Y-W, Cao L-H, Zhang J-B, Wang D-Z, Aisa HA. Synthesis and 
bioactivity of 5-(1-aryl-1H-tetrazol-5-ylsulfanylmethyl)-N-
xylopyranosyl-1, 3, 4-oxa (thia) diazol-2-amines. 
Carbohydrate research, 2011, 346, 551-559. 
14. Neetu Bharatiya CPG Green And Efficient Microwave One Pot 
Synthetic Approach to N-Phenyl Piperazinyl-1,3,4-Oxadiazole 
Derivatives and Evaluation of Their Antioxidant and Anti 
Inlammatory Activity. Indian Journal of Applied Research, 
2014, 4, 88-90. 
 
 
 
 
